Project name: Severe acute respiratory syndrome coronavirus 2

Description: AGILE is a rapid coronavirus drug testing initiative investigating several therapeutics for the treatment of COVID-19. This submission contains SARS-CoV-2 whole genome amplicon sequences derived from nasal swabs obtained on days 1, 3 and 5. Samples were taken to measure the primary outcome of viral load reduction (via qRT-PCR), with a small portion of each sample being redirected for more in-depth genomic analysis (via Illumina sequencing) to monitor for genetic changes in the virus.

Data type: raw sequence reads

Sample scope: Multiisolate

Relevance: Medical

Last updated: 2022-06-30